ISF35 / Memgen - LARVOL DELTA

A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL (clinicaltrials.gov) - P1b; N=13; Completed; Sponsor: Memgen, LLC; Active, not recruiting ➔ Completed; Phase classification: P1 ➔ P1b

Phase classification • Trial completion • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology • CD19 • CD20 • CD5 • FCER2 • TP53